ClinicalTrials.gg
RecruitingNCT07246135LPRUpdated Nov 5, 2026

Leadless Pacemaker Registry: Outcomes and Follow-up From the University Hospital of St. Pölten

An observational study in Pacemaker, Leadless Pacemaker and Cardiac Pacing, Artificial, sponsored by Karl Landsteiner University of Health Sciences. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Karl Landsteiner University of Health Sciences · Observational

How we know

From the registry’s dates

  • Started Jun 2015; still recruiting 11 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
700
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Bradycardia with a site in Austria — 7 open to participants now, 7 under way, none of them phase 3. Bradycardia · Austria.

Planned enrollment
7th of 11
700 · median 870
Started
2015
the only one that year
Observational
11 of 26
5 open now
Registered
24th of 26
by date
Lead sponsor
2 of 26
Karl Landsteiner University of Health Sciences

Among the 26 studies in Bradycardia with a site in Austria, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2015, is one of 11 observational ones, and was the 24th registered.

Bradycardia

317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.

Browse Bradycardia studies →

Open to participants now

7 of the 26 studies in Bradycardia with a site in Austria are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 51 Bradycardia studies recruiting now, 34 (67%) set no upper age limit and 9 (18%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Bradycardia with a site in Austria, or all of them as a file.
02

Study summary

The registry for leadless pacemakers will collect and annually analyze the data of all leadless pacemaker implantations at the University Hospital St. Pölten, including demographic information, indications, procedural details, acute, medium- and long-term complications during follow-up. Due to the partially novel nature of the signals (atrial mechanical sensing markers) and the lack of long-term experience to date, data on these aspects will also be collected and analyzed.

This is a single-center, prospective and retrospective registry that includes all patients receiving a leadless pacing device, as well as all patients who received a leadless pacing device between January 2021 and the start of the registry. All patients undergoing implantation of a leadless pacemaker will be invited to participate in the registry. For patients to be included retrospectively, participation in the registry will be offered at the time of their next routine follow-up visit.

The indication for leadless pacing will be determined by the physician responsible for the patient. Enrollment in the registry will in no case alter or influence the treatment the patient receives. Data collection will take place at the time of implantation and continuously during follow-up over the entire study period. Pacemaker-related data may be obtained either in person or via remote monitoring.

03

Conditions studied

  • Pacemaker
  • Leadless Pacemaker
  • Cardiac Pacing, Artificial
  • Registries

Browse trials for

Keywords

  • Registry
  • Leadless Pacemaker
  • Pacemaker
  • Cardiac Pacing
  • Pacemaker Complication
  • Leadless Pacemaker Outcomes
  • Heart Conduction System Disease
  • Bradycardia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients undergoing implantation of a leadless pacemaker at University Hospital St. Pölten, as well as patients who previously received a leadless pacemaker at the same institution since June 2015. Both prospective and retrospective patients are included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing implantation of a leadless pacemaker at the University Hospital of St. Pölten
  • Patients who previously received a leadless pacemaker between June 2015 and the start of the registry (retrospective inclusion).
  • Age ≥ 18 years.
  • Written provided by the patient.

Exclusion criteria

Exclusion Criteria:

  • Patients who decline or are unable to provide .
  • Patients in whom a conventional transvenous pacemaker is implanted (i.e., not leadless).
  • Any condition that, in the opinion of the treating physician, precludes participation in the registry.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
700 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Procedural success rate

    Successful implantation of a leadless pacemaker with acceptable electrical parameters and no need for conversion to a transvenous system

    Time frame: Periprocedural / at Day 1

  2. Incidence of acute complications

    Rate of periprocedural complications (e.g., vascular complications, arrhythmias, pericardial effusion, device dislodgement)

    Time frame: Within 30 days after implantation

Secondary outcomes

  1. Device-related complication rate (medium- and long-term)

    Cumulative incidence of complications requiring medical or surgical intervention (e.g., device malfunction, infection, need for extraction, upgrade)

    Time frame: Up to 10 years after implantation

  2. Ventricular pacing burden

    Percentage of ventricular pacing and triggered pacing as recorded by device interrogation

    Time frame: Day 1, 3 months post-implant (±2 weeks), 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter

  3. All-cause mortality

    Time frame: Throughout follow-up (up to 10 years)

  4. Hospitalizations related to cardiac arrhythmias or heart failure

    Time frame: Throughout follow-up (up to 10 years)

  5. Quality of Life after Implantation

    Change in 12-Item Short Form Health Survey (SF-12) questionnaire score / The SF-12 questionnaire is a validated health-related quality of life instrument with two subscales: Physical Component Summary (PCS) and Mental Component Summary (MCS). Each subscale ranges from 0 to 100 points, where higher scores indicate better health-related quality of life.

    Time frame: 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter

  6. Electrical performance of the device

    Pacing thresholds (in Volts at 0.24 ms pulse width)

    Time frame: Day 1, 3 months post-implant (±2 weeks), 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter

  7. Electrical performance of the device

    Sensing Amplitude (R-wave, in millivolts \[mV\])

    Time frame: Day 1, 3 months post-implant (±2 weeks), 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter

  8. Electrical performance of the device

    Lead impedance (in Ohms \[Ω\])

    Time frame: Day 1, 3 months post-implant (±2 weeks), 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter

  9. Electrical performance of the device

    Estimated battery longevity (in years)

    Time frame: Day 1, 3 months post-implant (±2 weeks), 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter

  10. Left ventricular ejection fraction on Echocardiography

    in %

    Time frame: 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter

  11. Left ventricular dimensions on Echocardiography

    end-diastolic and end-systolic diameters, in mm

    Time frame: 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter

  12. Right ventricular function on Echocardiography

    Tricuspid Annular Plane Systolic Excursion (TAPSE) in mm

    Time frame: 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter

07

Study locations

1 of 1 sites recruiting
  • University Hospital of St. Pölten
    Sankt Pölten, Lower Austria 3100, Austria
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2015 (actual). Primary completion is estimated for Jan 2035, 235 months after the start.

Of 73 observational studies under Bradycardia, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 96. This study's planned 235 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Nov 24, 2025
StartActual
Jun 18, 2015
Primary completionEst.
Jan 2035
CompletionEst.
Jan 2035
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07246135
Lead sponsor
Karl Landsteiner University of Health Sciences
Collaborators
University Hospital St. Polten
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Jun 18, 2015
Primary completion
Jan 2035 (estimated)
Completion
Jan 2035 (estimated)
Last update
Nov 5, 2026

Study contacts

Matthias Granner, MD
Contact
matthias.granner@stpoelten.lknoe.at
+432742900422632
Department of Internal Medicine III
Contact
interne3@stpolten.lknoe.at
+432742900412541
Julia Mascherbauer, MD, Professor
principal investigator · Department of Internal Medicine III, University Hospital of St. Pölten

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion